Granules India has received a license from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG). Developed by DRDO, 2-DG has been granted permission by the Drug Controller General of India (DCGI) for emergency use as an adjunct therapy in moderate to severe COVID-19 patients.
The company is working closely with the DRDO team to launch the product in India at the earliest. The drug reduces a patient's average recovery time by two and half days and oxygen demand by up to 40 percent.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
